18 March 2025

World Federation of Hemophilia

UPDATE: Global Discontinuation of HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Recombinant coagulation factor VIII, octocog alfa]

The purpose of this letter is to inform you that Takeda has decided to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Recombinant coagulation factor VIII, octocog alfa].

This was not a decision we made lightly. As the treatment landscape evolves, we decided to discontinue these medicines as patients continue to transition to alternative treatment options for hemophilia A, including those within our own hematology portfolio. While the standard of care and specific treatments available may vary, we took care to confirm that appropriate alternative treatments are available for patients in all markets impacted by this decision.

It is important to note there is no quality issue with HEMOFIL M or RECOMBINATE and that the safety and efficacy remains consistent with the product Prescribing Information / Summary of Product Characteristics.

We understand the significant impact this has on patients who rely on these medications and are committed to supporting the hemophilia community throughout this transition. We intend to supply HEMOFIL M and RECOMBINATE to patients already receiving these medicines until inventory is depleted or expired in mid-2026. Exact timing will vary based on potency and demand.

We encourage patients to contact their healthcare team to begin discussions and allow for sufficient time to develop long-term, alternative treatment plans.

We remain steadfastly committed to supporting patients throughout this discontinuation. If you have any questions, please contact us.

Yours sincerely,

Tineke Zuurbier
Head, Global Policy and Advocacy
Plasma Derived Therapies

Hampton Shaddock
Head, Global Therapeutic Policy and Patient Advocacy
Global Product Launch and Strategy